Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
Key facts
- Who runs it
- Novo Nordisk A/S
- Where
- Arlington, Boston, Chandler, Chicago, Dallas, Edinburg, Fort Myers, Hermitage, Hialeah, Houston, Jacksonville, Lancaster, Las Vegas, Miami, Pasadena, Philadelphia, Pittsburgh, Rochester, San Antonio, Shreveport, Springboro, Sugar Land, Topeka, Tucson, University Park, and Waco, United StatesSee the 29 sitesAlso in 13 other countries, 72 sites
- Trial code
- NCT06409130
- EU 2023-508170-28-00
- U1111-1295-6713
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 270 people enrolled
- Started
- 20 May 2024
- Ended
- 12 Jan 2026
- Type of study
- Interventional, 7 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- NNC0194-0499
- Semaglutide
- NNC0194-0499 placebo
- Semaglutide placebo (Group A)
- Cagrilintide + semaglutide
- Cagrilintide
- Cagrilintide placebo
- Semaglutide placebo (Group B)
- Record updated
- 12 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study
- Age 18 years or above, and at the legal drinking age according to local requirements at the time of signing the informed consent
- Patient-reported history of alcohol overuse for greater than or equal to 5 years with an alcohol history of a mean of greater than or equal to 50 grams (male)/40 grams (female) pr day for the last year leading up to the time of signing informed consent
- Enhanced Liver Fibrosis (ELF) greater than or equal to 9.0 units
Who cannot take part
- Previous participation (i.e., signed informed consent) in this study. If exclusion criteria 7 is met (Vibration Controlled Transient Elastography liver stiffness measurement (LSM) is greater than or equal to 25 Kilopascal (kPa)), a single rescreening is possible at the investigator's discretion
- Known or suspected hypersensitivity to study intervention(s) or related products (incl. excipients)
- Documented causes of chronic liver disease other than Alcohol-related liver disease (ALD)
- Positive hepatitis B surface antigen (HBsAg), positive human immunodeficiency virus-1 (HIV-1) or HIV-2 antibody (Ab), positive hepatitis C virus (HCV) ribonucleic acid (RNA) at screening (V1) or any known presence of HCV RNA or HBsAg within 2 years of screening visit 1 (V1)
- Presence or history of ascites more than grade 1, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or liver transplantation at screening (V1)
- Alcohol hepatitis at randomisation (as defined by National Institute on Alcohol Abuse and Alcoholism (NIAAA))
- Presence or history of gastro-oesophageal varices greater than or equal to grade 2* at V2. For participants with LSM greater than or equal to 20 kPa as well as blood platelets count less than 150,000 per microliter (μL) of blood an oesophagogastroduodenoscopy performed no more than 52 weeks prior to V2 must be available at V2. *Grade 2: varices projecting by one-third of the luminal diameter that cannot be compressed with air insufflation4
- Vibration Controlled Transient Elastography liver stiffness measurement (LSM) greater than or equal to 25 kPa at visit 2 (V2). If participants meet this criterion, rescreening is allowed once
- Body mass index (BMI) less than or equal to 25 Kilogram Per Square Meter (kg/m\^2)
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method with low user-dependency
Where in United States
Also in 13 other countries, 72 sites
- Texas Clinical Research InstituteArlington, United States
- Boston Medical Center_CaryBoston, United States
- The Institute for Liver HealthChandler, United States
- Rush University Med. CntrChicago, United States
- The Liver InstituteDallas, United States
- South Texas Research InstituteEdinburg, United States
- Covenant Metabolic Specialists, LLCFort Myers, United States
- Digestive Health Research, TNHermitage, United States
- Miguel Rebollar PAHialeah, United States
- Baylor St. Luke's Medical CenterHouston, United States
- Houston Research InstituteHouston, United States
- UF Hlth JacksonvilleJacksonville, United States
- Om Research LLCLancaster, United States
- Jubilee Clinical Research, Inc.Las Vegas, United States
- Univ of Miami/Schiff CtrMiami, United States
- California Liver Research InstitutePasadena, United States
- University of Pennsylvania HospitalPhiladelphia, United States
- UPMC_Center for Liver CarePittsburgh, United States
- Mayo Clinic - RochesterRochester, United States
- Amer. Rrsch Corp-TX Liver InstSan Antonio, United States
- Pinnacle Clinical ResearchSan Antonio, United States
- Louisiana Research Center, LLCShreveport, United States
- DSI Research, LLCSpringboro, United States
- Liver Specialists of TexasSugar Land, United States
- Kansas Medical Clinic PATopeka, United States
- Arizona Liver CenterTucson, United States
- Del Sol Research Management, LLCTucson, United States
- Covenant Metabolic Specialists, LLCUniversity Park, United States
- Velocity Clinical Res, WacoWaco, United States
About the trial
What the trial wants to find out
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.
The 7 groups in the trial
- NNC0194-0499 + semaglutideTreatment being tested
Group A: Participants will receive subcutaneous (s.c.) injections of NNC0194-0499 in combination with semaglutide.
Treatment: NNC0194-0499 and Semaglutide
- NNC0194-0499 + semaglutide placeboTreatment being tested
Group A: Participants will receive subcutaneous (s.c.) injections of NNC0194-0499 in combination with semaglutide placebo.
Treatment: NNC0194-0499 and Semaglutide placebo (Group A)
- NNC0194-0499 placebo + semaglutideTreatment being tested
Group A: Participants will receive subcutaneous (s.c.) injections of NNC0194-0499 placebo in combination with semaglutide.
Treatment: Semaglutide and NNC0194-0499 placebo
- NNC0194-0499 placebo + semaglutide placeboPlacebo, for comparison
Group A: Participants will receive subcutaneous (s.c.) injections of NNC0194-0499 placebo in combination with semaglutide placebo.
Treatment: NNC0194-0499 placebo and Semaglutide placebo (Group A)
- CagriSemaTreatment being tested
Group B: Participants will receive subcutaneous (s.c.) injection of cagrilintide in combination with semaglutide.
Treatment: Cagrilintide + semaglutide
- Cagrilintide + semaglutide placeboTreatment being tested
Group B: Participants will receive subcutaneous (s.c.) injection of cagrilintide in combination with semaglutide placebo.
Treatment: Cagrilintide and Semaglutide placebo (Group B)
- Cagrilintide placebo + semaglutide placeboPlacebo, for comparison
Group B: Participants will receive subcutaneous (s.c.) injection of cagrilintide placebo in combination with semaglutide placebo.
Treatment: Cagrilintide placebo and Semaglutide placebo (Group B)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Effects of NNC0194-0499 Alone and in Combination With Semaglutide, of Semaglutide Alone, and of Cagrilintide Alone and in Combination With Semaglutide on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
- Record updated
- 12 March 2026